Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyBryte and Visible-Light Activation in Cutaneous T-Cell Lymphoma
NCT06470451Phase 3Terminated
- Sponsor
- Soligenix
- Start
- Jan 2025
- Primary completion
- May 2026
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cutaneous T-cell lymphoma (CTCL) comparing HyBryte (0.25% Hypericin) with Placebo (2 arms). Primary endpoint: Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity at 18 weeks. Started Jan 2025; status: terminated.
02
Drugs
hypericin
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT06470451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470451.